Compare NRG Energy Inc (NRG) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Novavax Inc — how do they compare? NRG Energy Inc trades at $116.71 (market cap $24.25B), while Novavax Inc trades at $9.84 (market cap $1.62B). The key difference: NRG Energy Inc is far larger — about 15× Novavax Inc's market cap, and NRG Energy Inc pays a 1.65% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NRG | NVAX | |
|---|---|---|
Market Cap | $24.25B | $1.62B |
Sector | Utilities | Health |
52-Week High | $184.03 | $11.19 |
52-Week Low | $109.51 | $6.22 |
Enterprise Value | $48.21B | $1.20B |
Dividend Yield | 1.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $119.64, up 0.52% on the day, with a bullish technical signal and key support at $118. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is pursuing growth via a 1.2 GW Texas data center power project and reaffirmed 2026 guidance, while analyst consensus remains strongly positive with a $201.29 price target.
The outlook is supported by strategic investments in data center demand and shareholder returns, but risks include rising interest costs, high leverage, and execution challenges. The stock offers significant upside to analyst targets if growth initiatives deliver, though near-term volatility may persist amid earnings misses and macroeconomic pressures.
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
